A Phase 1 Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Ipafricept (Primary)
- Indications Fibroma; Pancreatic cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors OncoMed Pharmaceuticals
- 16 Sep 2016 Status changed from active, no longer recruiting to completed.
- 14 Apr 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
- 14 Apr 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History